Arcutis Biotherapeutics (ARQT) Amortization of Deferred Charges (2022)

Arcutis Biotherapeutics' Amortization of Deferred Charges history runs 7 years deep, the most recent figure standing at $111000.0 for Q1 2025.

• In Q1 2025, Amortization of Deferred Charges rose 14.43% year-over-year to $111000.0; the TTM figure through Mar 2025 stood at $422000.0 (up 14.05% YoY), while the FY2024 annual figure was $408000.0, up 13.33% from the prior year.
• Amortization of Deferred Charges for Q1 2025 stood at $111000.0, up from $107000.0 in the prior quarter.
• The five-year high for Amortization of Deferred Charges was $158000.0 in Q2 2021, with the low at $75000.0 in Q4 2021.
• The 5-year median for Amortization of Deferred Charges is $89500.0 (2023), against an average of $94187.5.
• The sharpest annual moves came in 2021 and 2022: Amortization of Deferred Charges jumped 485.19% in 2021, then plunged 50.0% in 2022.
• Arcutis Biotherapeutics' Amortization of Deferred Charges stood at $75000.0 in 2021, then climbed by 9.33% to $82000.0 in 2022, then increased by 14.63% to $94000.0 in 2023, then increased by 13.83% to $107000.0 in 2024, then grew by 3.74% to $111000.0 in 2025.
• Business Quant data shows ARQT's Amortization of Deferred Charges at $111000.0 in Q1 2025, $107000.0 in Q4 2024, and $103000.0 in Q3 2024.